Filing Details

Accession Number:
0001181431-10-063677
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-12-27 19:23:35
Reporting Period:
2010-12-27
Filing Date:
2010-12-27
Accepted Time:
2010-12-27 19:23:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1295976 Cellu Tissue Holdings Inc. CLU Paper Mills (2621) 061346495
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1473977 Sean R. Honey 1855 Lockeway Drive
Suite 501
Alpharetta GA 30004
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2010-12-27 1,923 $12.00 0 No 4 D Direct
Common Stock Disposition 2010-12-27 9,911,317 $12.00 0 No 4 S Indirect By Invest. entity
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 D Direct
No 4 S Indirect By Invest. entity
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option Disposition 2010-12-27 4,654 $0.00 4,654 $11.45
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2020-01-27 No 4 D Direct
Footnotes
  1. On December 27, 2010, a wholly owned subsidiary of Clearwater Paper Corporation merged with Cellu Tissue Holdings, Inc. pursuant to a merger agreement entered into between Clearwater Paper and Cellu Tissue on September 15, 2010 (the "Merger"), as more fully described in the Cellu Tissue proxy statement dated December 1, 2010 filed with the SEC. Each share of common stock of Cellu Tissue was converted into $12.00 in cash. Cellu Tissue board of directors approved the disposition by the Reporting Person in the Merger.
  2. Reporting person is a non-managing member of the general partner of Weston Presidio V, L.P., a 10% owner of Issuer. Reporting person may be deemed to have an indirect interest in the securities held by Weston Presidio V, L.P. Reporting person disclaims beneficial ownership in the securities except to the extent of his pecuniary interest therein. Shares sold in the Merger described above.
  3. In connection with the Merger, each outstanding Cellu Tissue option to purchase shares of common stock, whether or not vested, was cancelled and Reporting Person received a cash payment in an amount equal to the number of shares of common stock represented by each option, vested or unvested, multiplied by the excess, if any, of $12.00 over the exercise price per share under each option. Reporting Person's disposition of options in the Merger was approved by the Cellu Tissue board of directors.